Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMED Globus Medical	$59.10 -2.4%	$61.38	$54.48 ▼ $94.93	$8.01B	1.19	1.14 million shs	1.81 million shs
HAE Haemonetics	$76.85 +0.8%	$69.41	$55.30 ▼ $94.99	$3.69B	0.39	673,113 shs	249,556 shs
IART Integra LifeSciences	$13.49 -0.3%	$13.18	$11.06 ▼ $32.66	$1.05B	1.15	973,046 shs	759,134 shs
NVRO Nevro	$5.85 +0.1%	$5.85	$3.17 ▼ $10.37	$224.32M	0.81	800,223 shs	753,602 shs
TNDM Tandem Diabetes Care	$17.06 -0.1%	$20.53	$15.75 ▼ $48.24	$1.12B	1.48	1.48 million shs	1.10 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMED Globus Medical	0.00%	+0.96%	-0.60%	-14.36%	-13.84%
HAE Haemonetics	0.00%	+3.89%	+9.07%	+26.40%	-8.71%
IART Integra LifeSciences	0.00%	+9.72%	+1.47%	-31.09%	-53.06%
NVRO Nevro	0.00%	0.00%	0.00%	0.00%	-30.24%
TNDM Tandem Diabetes Care	0.00%	-9.90%	-17.41%	+1.09%	-57.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMED Globus Medical	4.9493 of 5 stars	4.3	5.0	4.1	2.5	2.5	1.9
HAE Haemonetics	4.8712 of 5 stars	4.5	2.0	4.3	2.4	1.7	2.5
IART Integra LifeSciences	4.0836 of 5 stars	2.9	1.0	4.0	1.4	1.7	2.5
NVRO Nevro	0.171 of 5 stars	1.0	0.0	0.0	0.0	1.7	0.6
TNDM Tandem Diabetes Care	4.2905 of 5 stars	4.2	1.0	4.9	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMED Globus Medical	2.62	Moderate Buy	$94.00	59.05% Upside
HAE Haemonetics	2.91	Moderate Buy	$96.80	25.97% Upside
IART Integra LifeSciences	1.78	Reduce	$18.63	38.12% Upside
NVRO Nevro	1.92	Reduce	$5.36	-8.29% Downside
TNDM Tandem Diabetes Care	2.40	Hold	$33.43	95.90% Upside

Current Analyst Ratings Breakdown

Latest HAE, NVRO, TNDM, IART, and GMED Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/25/2025	HAE Haemonetics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$24.00
6/10/2025	GMED Globus Medical	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/27/2025	GMED Globus Medical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/27/2025	GMED Globus Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/22/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $24.00
5/20/2025	HAE Haemonetics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$100.00 ➝ $100.00
5/12/2025	GMED Globus Medical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$80.00 ➝ $68.00
5/9/2025	GMED Globus Medical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $80.00
5/9/2025	HAE Haemonetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$115.00 ➝ $105.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMED Globus Medical	$2.51B	3.19	$6.65 per share	8.89	$30.40 per share	1.94
HAE Haemonetics	$1.36B	2.71	$7.20 per share	10.67	$16.34 per share	4.70
IART Integra LifeSciences	$1.61B	0.65	$4.45 per share	3.03	$20.03 per share	0.67
NVRO Nevro	$408.52M	0.55	N/A	N/A	$8.10 per share	0.72
TNDM Tandem Diabetes Care	$940.20M	1.21	N/A	N/A	$4.01 per share	4.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMED Globus Medical	$102.98M	$1.34	44.10	14.67	1.72	7.39%	10.52%	8.56%	8/5/2025 (Estimated)
HAE Haemonetics	$167.68M	$3.31	23.22	15.25	1.25	12.32%	26.37%	9.22%	8/14/2025 (Estimated)
IART Integra LifeSciences	-$6.94M	-$0.38	N/A	5.39	0.75	-1.78%	12.12%	4.58%	8/4/2025 (Estimated)
NVRO Nevro	-$92.21M	-$3.05	N/A	N/A	N/A	-16.54%	-23.52%	-10.83%	8/4/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$2.78	N/A	N/A	N/A	-18.71%	-57.33%	-13.48%	8/6/2025 (Confirmed)

Latest HAE, NVRO, TNDM, IART, and GMED Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMED Globus Medical	$0.74	$0.68	-$0.06	$0.54	$629.74 million	$598.12 million
5/8/2025	Q4 2025	HAE Haemonetics	$1.22	$1.24	+$0.02	$1.17	$329.38 million	$330.60 million
5/5/2025	Q1 2025	IART Integra LifeSciences	$0.43	$0.41	-$0.02	-$0.33	$381.17 million	$382.65 million
4/30/2025	Q1 2025	TNDM Tandem Diabetes Care	-$0.60	-$0.67	-$0.07	-$1.97	$220.19 million	$234.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
IART Integra LifeSciences	N/A	N/A	N/A	N/A	N/A
NVRO Nevro	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMED Globus Medical	N/A	4.45	2.72
HAE Haemonetics	1.12	1.62	0.99
IART Integra LifeSciences	0.81	1.21	0.72
NVRO Nevro	0.67	5.02	3.76
TNDM Tandem Diabetes Care	1.99	2.30	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMED Globus Medical	95.16%
HAE Haemonetics	99.67%
IART Integra LifeSciences	84.78%
NVRO Nevro	95.52%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
GMED Globus Medical	18.51%
HAE Haemonetics	1.84%
IART Integra LifeSciences	3.54%
NVRO Nevro	3.20%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMED Globus Medical	5,300	135.38 million	110.32 million	Optionable
HAE Haemonetics	3,023	48.04 million	47.16 million	Optionable
IART Integra LifeSciences	4,396	77.71 million	74.96 million	Optionable
NVRO Nevro	1,090	38.37 million	36.27 million	Optionable
TNDM Tandem Diabetes Care	2,650	66.61 million	65.34 million	Optionable

HAE, NVRO, TNDM, IART, and GMED Headlines

Recent News About These Companies

Mirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

July 6 at 3:35 AM | marketbeat.com

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Morningstar

July 2, 2025 | morningstar.comM

RSI Alert: Tandem Diabetes Care (TNDM) Now Oversold

July 2, 2025 | nasdaq.com

TNDM - Tandem Diabetes Care Inc Key Metrics - Morningstar

July 1, 2025 | morningstar.comM

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 1, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's Why

July 1, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $33.43 Consensus Price Target from Brokerages

June 28, 2025 | americanbankingnews.com

TNDM - Tandem Diabetes Care Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

The 5 Most Interesting Analyst Questions From Tandem Diabetes’s Q1 Earnings Call

June 27, 2025 | msn.com

TNDM | Tandem Diabetes Care Inc. Annual Cash Flow Statement - MarketWatch

June 26, 2025 | marketwatch.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Down 5.9% - Time to Sell?

June 25, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Hold" by Brokerages

June 25, 2025 | marketbeat.com

Tandem Diabetes Care Inc TNDM Company Vitals - U.S. News

June 24, 2025 | money.usnews.com

TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3

June 24, 2025 | msn.com

TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +

June 23, 2025 | zacks.com

Tandem continues to deliver more options, benefits for those with diabetes

June 22, 2025 | massdevice.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes

June 20, 2025 | drugdeliverybusiness.comD

Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.

June 20, 2025 | drugdeliverybusiness.comD

Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States

June 20, 2025 | uk.finance.yahoo.com

Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

June 20, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE, NVRO, TNDM, IART, and GMED Company Descriptions

Globus Medical NYSE:GMED

$59.10 -1.47 (-2.43%)

Closing price 07/3/2025 03:34 PM Eastern

Extended Trading

$59.10 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics NYSE:HAE

$76.84 +0.61 (+0.79%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$76.84 0.00 (0.00%)

As of 07/3/2025 04:04 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Integra LifeSciences NASDAQ:IART

$13.48 -0.04 (-0.26%)

Closing price 07/3/2025 02:35 PM Eastern

Extended Trading

$13.48 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)

Closing price 04/2/2025

Extended Trading

$5.85 0.00 (0.00%)

As of 04/2/2025 07:56 PM Eastern

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Tandem Diabetes Care NASDAQ:TNDM

$17.06 -0.02 (-0.09%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$16.72 -0.34 (-2.02%)

As of 07/3/2025 04:20 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time